
|Articles|February 1, 2005
Imiquimod may potentiate melanoma vaccine effect
Newport Beach, Calif. — The immune response modifier imiquimod (Aldara, 3M Pharmaceuticals) may have a role as an enhancer of other immunotherapies for melanoma, Noah Craft, M.D., Ph.D. said here at the annual meeting of the Pacific Dermatologic Association (PDA).
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
3
Introducing Dermatology Times NP/PA Connect
4
Narrow-Spectrum Sarecycline Approved for Moderate to Severe Acne in China
5











